Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets ... Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. 詳細を表示
WESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.65 | 16.3727959698 | 3.97 | 4.78 | 3.8 | 36517 | 4.42067115 | CS |
4 | -1.6 | -25.7234726688 | 6.22 | 7.11 | 3.8 | 41668 | 5.09440119 | CS |
12 | 0.07 | 1.53846153846 | 4.55 | 23.01 | 2.81 | 1005260 | 9.53879403 | CS |
26 | -0.38 | -7.6 | 5 | 23.01 | 2.098 | 1287540 | 6.74927928 | CS |
52 | -23.78 | -83.7323943662 | 28.4 | 40.8 | 2.098 | 704708 | 6.95438554 | CS |
156 | -380.58 | -98.800623053 | 385.2 | 407.43 | 2.098 | 251576 | 15.14444552 | CS |
260 | -745.38 | -99.384 | 750 | 899.526 | 2.098 | 208520 | 31.17371337 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約